Bristol-Myers Squibb Company (BMY) closed at $62.14 on November 9, 2026, unchanged from the previous close, on volume of 6,846,879 shares (30-day average 12,121,020).
Data as of November 9, 2026.
9-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Put Spread Tied to Stock | 18-Dec-2655 : 57.5 P +155,000 Stock | 39,720 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Tue, 10-Nov 2:40 AM ET)
Bristol says long-term Camzyos data buoys treatment in children
Seeking Alpha News (Fri, 6-Nov 5:22 PM ET)
Business Wire (Fri, 6-Nov 4:00 PM ET)
Democratic lawmakers seen probing Trump drug pricing deals come January
Seeking Alpha News (Fri, 6-Nov 12:13 PM ET)
Leading Academic Medical Centers to Present New AI-ECG Research on Viz.ai's Cardio Suite at AHA 2026
Business Wire (Fri, 6-Nov 9:12 AM ET)
Half of RFK Jr. health panel appointees granted waivers to keep stocks: NY Times
Seeking Alpha News (Thu, 5-Nov 4:49 PM ET)
Bristol-Myers Squibb Updates Real-World Lung Cancer Study
TipRanks (Thu, 5-Nov 11:31 AM ET)
Bristol Myers Squibb Updates Taiwan Luspatercept Study: What Investors Should Know
TipRanks (Thu, 5-Nov 11:30 AM ET)
2027 Could Finally Be the Year Cancer Is on the Ropes!
Globe Newswire (Thu, 29-Oct 9:10 PM ET)
Bristol Myers Squibb Sets 8:00 a.m. ET Webcast for Q3 2026 Results as Investors Await Details
Market Chameleon (Thu, 29-Oct 4:09 AM ET)
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Bristol-Myers Squibb Company trades on the NYSE stock market under the symbol BMY.
As of November 9, 2026, BMY stock price was flat at $62.14 with 6,846,879 million shares trading.
BMY has a beta of -0.10, meaning it tends to be less sensitive to market movements. BMY has a correlation of 0.00 to the broad based SPY ETF.
BMY has a market cap of $127.02 billion. This is considered a Large Cap stock.
Last quarter Bristol-Myers Squibb Company reported $13 billion in Revenue and $1.35 earnings per share. This beat revenue expectation by $374 million and exceeded earnings estimates by $.11.
In the last 3 years, BMY traded as high as $68.64 and as low as $39.35.
The top ETF exchange traded funds that BMY belongs to (by Net Assets): VTI, SCHD, VOO, IVV, SPY.
BMY has outperformed the market in the last year with a price return of +38.7% while the SPY ETF gained +13.4%. However, in the short term, BMY had mixed performance relative to the market. It has underperformed in the last 3 months, returning -2.2% vs -1.8% return in SPY. But in the last 2 weeks, BMY shares have fared better than the market returning +1.1% compared to SPY -1.0%.
BMY support price is $60.75 and resistance is $63.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMY shares will trade within this expected range on the day.
